May 2014 Edition Vol.11, Issue 5

Can Innate Immune Cells Engage in Anti-Tumor Activity?

Can Innate Immune Cells Engage in Anti-Tumor Activity? (continued)

Potential of Immunotherapies

There is little doubt that the hope for new and significantly improved cancer therapies is focused on immunotherapy. New immunotherapeutic approaches are demonstrating exciting results in the clinic. Long-term survival, the gold standard for all cancer therapies, may well rest in understanding how immunotherapies can be combined to shift the immune cell balance of power in the battle going on in the tumor microenvironment. Perhaps, it is a battle of numbers and the discovery of the ability to redirect the large populations of innate cells, like neutrophils and monocytes, to join the attack against cancer may markedly alter clinical outcomes.

By Myra Patchen, Ph.D., Chief Scientific Officer, Biothera

 

About Biothera

Biothera is biotechnology company that is developing a phase 3 cancer immunotherapy, Imprime PGG® for multiple indications, including colorectal cancer, non-small cell lung cancer, chronic lymphocytic leukemia and non-Hodgkin lymphoma. While other cancer immunotherapies elicit adaptive immune responses, Imprime PGG engages and redirects innate immune cells to kill antibody-targeted cancer cells.

 

Citations

1 Yervoy (ipililmumab) Package Insert; Highlights of Prescribing Information. Bristol-Myers Squibb. 2011.

2 Schadendorf D, Hodi FS, Robert C, et al.  Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. European Cancer Congress, 2013; Abstract LBA24; Presented September 28, 2013.

3 Hodi FS, O’Day SJ, McDermott DF.  et al.  Improved survival with ipilimumab in patients with metastatic melanoma. New Eng J Med. 2010; 363:711-723.

4 Sznol M, Kluger HM, Hodi FS, et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol. 2013; 31 (suppl; abstr CRA9006).

5 Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Eng J Med. 2013;369:134-144.

6 Shaffer, A. Immunotherapy Hits New Peak: ASCO Data Stir Excitement, Investment. OncLive; Aug 21, 2013.

7 Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol. 2002; 168:1964–1970. 

Stuttmann H, Riemensberger J, Bebtien G, et al.  Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses.  Cancer Research. 2006; 66:8250-8257.

9 Li B, Allendorf DJ, Hansen R, et al.  Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway.  J Immunol. 2006; 177:1661-1669.

10 Salvador C, Li B, Hansen R, et al.  Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models.  Clin Cancer Res., 2008; 14:1239-1247.

11 Qi C, Cai Y, Gunn L, et al.  Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans. Blood. 2011; 117:6825-6836.

12 Tamayo, M.E., Cornelio, G.H., Bautista, J.B., Flores, M.L., Tioleco, P.S., Kurman, M.R., Vasilakos, J.V., Marsh, L.M., Gargano, M.A., Patchen, M.L. (2010)  Safety and efficacy of Imprime PGG plus cetuximab with irinotecan and without irinotecan in patients with advanced colorectal cancer (CRC): A Phase 1b/2 study with KRAS subpopulation analysis. 12th European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer, Barcelona, Spain. Annals of Oncology. 21 (Suppl 6) (Abstract #PD0009). 

13 Segal, N.H., Senzer, N., Gada, P.,  Marsh, L.M., Gargano, M.A., Patchen, M.L., Saltz L.  (2011)  Imprime PGG plus cetuximab therapy for advanced KRAS mutant colorectal cancer. 13th European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer, Barcelona, Spain. Annals of Oncology. 22 (Suppl 5) (Abstract #PD0013).

14 Zent C, LaPlant B, Call T, et al.  Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and PGG beta glucan: A Phase I clinical trial.  The American Society of Hematology (ASH) meeting, Atlanta  (Abstr # 1792). Blood. 2012;120.

15 Schneller, F., Thomas, M., Sadjadian, P., Kollmeier, J., Bose, N., Antonysamy, M., Patchen, M.,  Lowe, J., Mattson, P., Huhn, R. (2014)  PGG β-glucan with carboplatin, paclitaxel and cetuximab for chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC).  European Society of Medical Oncology (ESMO) and 4th European Lung Cancer Conference (ELCC), Geneva, Switzerland, Abstract #100PD.  J Thoracic Oncol. Vol 9 (Suppl 14), S40.

 

Pages: 1 2 3

Post a Comment

OBR Archives

To view previous issues of OBR green you can visit our archives. The entire library of OBR green articles is searchable.